Performance of ARCHITECT HCV core antigen test with specimens from US plasma donors and injecting drug users.
J Clin Virol
; 66: 15-8, 2015 May.
Article
em En
| MEDLINE
| ID: mdl-25866329
ABSTRACT
BACKGROUND:
Hepatitis C virus (HCV) core antigen is a serological marker of current HCV infection.OBJECTIVES:
The aim of this study was mainly to evaluate the performance characteristics of the ARCHITECT HCV core antigen assay with specimens from US plasma donors and injecting drug users. STUDYDESIGN:
A total of 551 serum and plasma samples with known anti-HCV and HCV RNA status were tested for HCV core antigen using the Abbott ARCHITECT HCV core antigen test.RESULTS:
HCV core antigen was detectable in 100% of US plasma donor samples collected during the pre-seroconversion phase of infection (anti-HCV negative/HCV RNA positive). Overall sensitivity of the HCV core antigen assay was 88.9-94.3% in samples collected after seroconversion. The correlation between HCV core antigen and HCV RNA titers was 0.959.CONCLUSIONS:
HCV core antigen testing may be reliably used to identify current HCV infection.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Plasma
/
Doadores de Sangue
/
Abuso de Substâncias por Via Intravenosa
/
Proteínas do Core Viral
/
Programas de Rastreamento
/
Hepatite C
/
Testes Diagnósticos de Rotina
/
Usuários de Drogas
/
Antígenos Virais
Tipo de estudo:
Diagnostic_studies
/
Evaluation_studies
/
Prognostic_studies
/
Screening_studies
Limite:
Humans
País como assunto:
America do norte
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article